Catalent

{{Infobox company

| name = Catalent, Inc.

| logo = File:Catalent logo.svg

| type = Privatehttps://www.catalent.com/catalent-news/novo-holdings-to-acquire-catalent/

| traded_as = {{NYSE was|CTLT}} (2014–2024)

| industry = Pharmaceuticals

| predecessor = Cardinal Health PTS

| founded = {{Start date and age|2007}}

| hq_location = Somerset, New Jersey, U.S.

| key_people = {{ubl|Alessandro Maselli |(President & CEO)| John Greisch (Chairman)}}

| services = Drug pre-formulation, formulation, analytical testing, clinical and commercial manufacturing, clinical packaging and supply chain, regulatory consulting

| revenue = {{increase}} {{US$|4.38 billion|link=yes}} (2024)

| operating_income = {{decrease}} {{US$|-749 million}} (2024)

| net_income = {{decrease}} {{US$|-1.04 billion}} (2024)

| assets = {{decrease}} {{US$|9.75 billion}} (2024)

| equity = {{decrease}} {{US$|3.60 billion}} (2024)

| parent = Novo Holdings A/S

| locations = 53 (2024)

| num_employees = 16,900 (2024)

| website = {{URL|catalent.com}}

| footnotes = Financials {{as of|2024|06|30|lc=y|df=US}}.{{Cite web |url=https://www.sec.gov/ix?doc=/Archives/edgar/data/1596783/000159678324000087/ctlt-20240630.htm |title=FY 2024 Annual Report (Form 10-K) | publisher=U.S. Securities and Exchange Commission | date=September 6, 2024}}

}}

Catalent, Inc. (Catalent Pharma Solutions), is an American multinational company, and a subsidiary of Novo Holdings A/S since 2024. It is headquartered in Somerset, New Jersey. It is a provider of drug delivery technologies, drug development, drug manufacturing, biologics, gene therapy, and consumer health products. It has over 50 facilities on four continents and has supported more than half the products approved by the Food and Drug Administration in the last ten years. Annually, it produces 70 billion doses for 8,000 products. The company's major customers include Bayer, Bristol-Myers Squibb, GlaxoSmithKline, Haleon, Novo Nordisk, Moderna, Pfizer, and Sarepta Therapeutics.

History

=Before 2007=

In 1996, Cardinal Health acquired PCI of Philadelphia, Pennsylvania, a pharmaceutical contract packing service for commercial and clinical packaging.{{cite news | url=https://www.nytimes.com/1996/07/25/business/company-news-cardinal-health-to-buy-pci-services-for-145-million.html | title=COMPANY NEWS;CARDINAL HEALTH TO BUY PCI SERVICES FOR $145 MILLION | agency=Bloomberg News | work=The New York Times | date=July 25, 1996 | url-access=limited}}{{Cite news | url=https://www.wsj.com/articles/SB838254265359152500 | title=Cardinal Health to Buy PCI In Deal Worth $201 Million | work=The Wall Street Journal | date=July 25, 1996 | url-access=subscription}}

In 1998, Cardinal Health acquired R.P. Scherer Corporation of Troy, Michigan for $2.2 billion; it was founded by Robert Pauli Scherer to commercialize his innovation of softgel encapsulation using the rotary die production process.{{Cite news | url=https://www.nytimes.com/1998/05/19/business/cardinal-health-in-surprise-2.2-billion-deal.html | title=Cardinal Health in Surprise $2.2 Billion Deal | first=David J. | last=Morrow | work=The New York Times | date=May 19, 1998 | url-access=limited}}{{cite news | url=https://www.wsj.com/articles/SB895506453762968500 | title=Cardinal Health Agrees to Acquire Scherer for $2.07 Billion in Stock | first=Rekha | last=Balu | work=The Wall Street Journal | date=May 19, 1998 | url-access=subscription}}{{cite news | url=https://manufacturingchemist.com/news/article_page/Catalent_completes_acquisition_of_R_P_Scherer_Eberbach/76286 | title=Catalent completes acquisition of R P Scherer Eberbach | work=Manufacturing Chemist |date=1 March 2012}}

In 1999, Cardinal Health acquired Automatic Liquid Packaging of Woodstock, Illinois, thereby entering the sterile product market with blow fill seal technology.{{cite news | url=https://www.pharmamanufacturing.com/production/aseptic-processing/article/11323107/container-innovations-prairie-home-catalent-pioneers-blow-fill-seal-aseptic-packaging

| title=Container Innovation's Prairie Home | last=Kuehn |first=Steven | publisher=Endeavor Business Media | date=6 October 2014}}

In January 2001, Cardinal Health acquired International Processing Corporation, a company that was renowned for its expertise in oral modified-release dosage form development and manufacturing, for $40 million.{{Cite news | url=https://www.bizjournals.com/columbus/stories/2001/01/08/daily7.html | title=Cardinal Health subsidiary completes acquisition | work=American City Business Journals | date=January 9, 2001 | url-access=subscription}} In April 2002, Cardinal Health acquired Magellan Laboratories, a company that specialized in product development expertise.{{Cite news | url=https://www.bizjournals.com/triangle/stories/2002/03/18/daily1.html | title=Cardinal Health to acquire Magellan | first1=Sabine | last1=Vollmer | first2=Chris | last2=Baysden | work=American City Business Journals | date=March 18, 2002 | url-access=subscription}}

In October 2003, Cardinal Health acquired Gala Biotech of Madison, Wisconsin for $15.5 million.{{Cite news | url=https://www.bizjournals.com/columbus/stories/2003/09/29/daily19.html | title=Cardinal buys out partners in biotech firm | work=American City Business Journals | date=September 29, 2003 | url-access=subscription}}

It also acquired Intercare Group of the UK for $530 million, broadening its global capabilities in Europe.{{Cite news | url=https://www.nytimes.com/2003/10/30/business/company-news-drug-wholesaler-to-buy-packaging-company.html | title=COMPANY NEWS; DRUG WHOLESALER TO BUY PACKAGING COMPANY | agency=Bloomberg News | work=The New York Times | date=October 30, 2003 | url-access=limited}}

=2007–2019=

In April 2007, the pharmaceutical technologies and services segment of Cardinal Health was acquired by affiliates of The Blackstone Group and re-branded as Catalent Pharma Solutions.{{cite news | title=Cardinal Health Completes Sale of Pharmaceutical Technologies and Services Segment to The Blackstone Group | url=https://www.blackstone.com/news/press/cardinal-health-completes-sale-of-pharmaceutical-technologies-and-services-segment-to-the-blackstone-group/ | publisher=The Blackstone Group | location=Dublin, Ohio | date=April 10, 2007}}{{Cite news | url=https://www.biospace.com/formerly-b-cardinal-health-pts-b-newly-named-catalent-now-operates-as-independent-company | title=Formerly Cardinal Health PTS, Newly Named Catalent Now Operates as Independent Company | work=Biospace | date=June 21, 2007}}

In February 2012, Catalent acquired Aptuit, a clinical supply company. As part of the deal, Catalent gained three sites in the US, two in the UK, and one in Singapore.{{Cite news | url=https://www.fiercebiotech.com/biotech/catalent-completes-acquisition-of-clinical-trials-supplies-business-of-aptuit-llc | title=Catalent Completes Acquisition Of Clinical Trials Supplies Business Of Aptuit LLC | work=Fierce Biotech | date=February 22, 2012}}{{cite news | url=https://www.biopharma-reporter.com/Article/2012/02/20/Catalent-completes-Aptuit-deal/ |title=Catalent completes Aptuit deal | work=BioPharma-reporter.com |date=20 February 2012}} Catalent also acquired all remaining shares for the R.P Scherer site in Eberbach, Germany.{{Cite news | title=2 big companies and 1 small one to target in the pharma/biotech space | url=https://www.thestreet.com/story/13697296/1/2-big-companies-and-1-small-one-to-target-in-the-pharma-biotech-space.html | last=Wasserman | first=Robert | work=TheStreet.com |date=2016-09-08}}

In March 2013, Catalent continued the global expansion of its Softgel capabilities through a joint venture with Zhejiang Jaing Yuan Tang Biotechnology, a China-based company, and Relthy Laboratories in Brazil.{{Cite news | url=https://cen.acs.org/articles/91/i11/Catalent-Sets-Chinese-Ventures.html | title=Catalent Sets Chinese Ventures | first=Jean-François | last=Tremblay | work=Chemical & Engineering News | date=March 18, 2013}}{{Cite news | url=https://www.genengnews.com/topics/bioprocessing/catalent-raises-china-stakes-with-two-deals/ | title=Catalent Raises China Stakes with Two Deals | work=Mary Ann Liebert | date=March 11, 2013}}

In July 2014, Catalent became a public company via an initial public offering on the New York Stock Exchange, raising $870 million.{{Cite news | url=https://www.biospace.com/b-catalent-inc-b-announces-pricing-of-its-initial-public-offering | title=Catalent, Inc. Announces Pricing of Its Initial Public Offering | publisher=Business Wire | date=July 31, 2014}}{{Cite news | url=https://fortune.com/2014/07/31/catalent-ipo/ | title=Catalent delivers with $871 million biotech IPO | first=Laura | last=Lorenzetti | work=Fortune | date=July 31, 2014 | url-access=subscription}}

In November 2014, Catalent acquired Micron Technologies, a provider of particle size engineering technologies, expanding its portfolio of drug delivery technologies.{{Cite news | url=https://www.pharmtech.com/view/catalent-acquires-micron-technologies-adds-particle-engineering-capabilities-portfolio | title=Catalent Acquires Micron Technologies, Adds Particle Engineering Capabilities to Portfolio | work=Pharmtech | date=November 13, 2014}}

In September 2016, Catalent acquired Pharmatek Laboratories to add spray drying capabilities.{{Cite news | url=https://www.genengnews.com/topics/drug-discovery/catalent-to-acquire-pharmatek/ | title=Catalent to Acquire Pharmatek | work=Mary Ann Liebert | date=September 13, 2016}}{{cite news | url=https://cen.acs.org/articles/94/i37/Catalent-buy-Pharmatek-Labs.html | title=Catalent will buy Pharmatek Labs | first=Ann M. | last=Thayer | work=Chemical & Engineering News | date=September 19, 2016 | url-access=limited}}

In October 2016, Catalent licensed the anti-body drug conjugate (ADC) to Triphase Accelerator to help with oncology development,{{Cite press release | url=https://www.globenewswire.com/en/news-release/2016/10/04/876905/0/en/Catalent-Biologics-and-Triphase-Accelerator-Corporation-Announce-License-Agreement-to-Advance-SMARTag-ADC-to-Clinic.html | title=Catalent Biologics and Triphase Accelerator Corporation Announce License Agreement to Advance SMARTag™ ADC to Clinic | publisher=GlobeNewswire | date=October 4, 2016}}

In September 2017, Catalent agreed to acquire Cook Pharmica for $950 million, expanding its biologic manufacturing.{{Cite news | url=https://www.reuters.com/article/business/catalent-to-buy-cook-pharmica-for-950-mln-idUSL4N1M03UW/ | title=Catalent to buy Cook Pharmica for $950 mln | first=Tamara | last=Mathias | editor-first=Sai Sachin | editor-last=Ravikumar | work=Reuters | date=September 19, 2017}}

In July 2018, Catalent acquired Juniper Pharmaceuticals for $133 million.{{Cite news |title=Catalent extends expansion with $133M deal for Juniper Pharmaceuticals | url=https://www.fiercepharma.com/manufacturing/catalent-extends-expansion-130m-deal-for-juniper-pharmaceuticals | first=Eric | last=Palmer | work=Fierce Pharma |date=3 July 2018}}

In March 2019, Catalent invested more than $27 million to commercialize Zydis Ultra. The investment includes new Zydis lines; changes to facilities in Swindon, UK; and a custom suite for commercial equipment.{{Cite news | url=https://www.pharmtech.com/view/catalent-invests-zydis-ultra-commercialization |title=Catalent Invests in Zydis Ultra Commercialization | work=PharmTech | date=20 March 2019}}

In September 2018, Catalent partnered with GB Sciences to develop a cannabinoid-derived medicine for Parkinson's disease utilizing the Zydis delivery method.{{Cite press release | url=https://www.prnewswire.com/news-releases/catalent-selected-to-provide-oral-delivery-systems-for-gb-sciences-proprietary-parkinsons-disease-therapies-300718037.html | title=Catalent Selected to Provide Oral Delivery Systems for GB Sciences' Proprietary Parkinson's Disease Therapies | publisher=PR Newswire | date=September 26, 2018}}

In May 2019, Catalent acquired Paragon Bioservices for $1.2 billion to expand its gene-therapy manufacturing capabilities.{{Cite news | url=https://www.fiercepharma.com/manufacturing/catalent-s-new-prize-paragon-adding-capacity-to-make-sarepta-gene-therapies | title=Catalent's new prize, Paragon, adding capacity to make Sarepta gene therapies | first=Eric | last=Palmer | work=Fierce Pharma | date=May 21, 2019}}{{Cite news | url=https://www.wsj.com/articles/catalent-to-buy-paragon-bioservices-for-1-2-billion-11555330948 | title=Catalent to Buy Paragon Bioservices for $1.2 Billion | first1=Kimberly | last1=Chin | first2=Jared S. | last2=Hopkins | work=The Wall Street Journal |date=15 April 2019 | url-access=subscription}} By October 2019, Paragon's employee count doubled since the April acquisition.{{Cite news | url=https://www.bizjournals.com/baltimore/news/2019/10/17/paragon-growing-quickly-toward-1-000-employees.html | title=Paragon growing quickly toward 1,000 employees after Catalent acquisition | first=Morgan | last=Eichensehr | work=American City Business Journals | date=October 17, 2019 | url-access=subscription |archive-url=https://web.archive.org/web/20201029165951/https://www.bizjournals.com/baltimore/news/2019/10/17/paragon-growing-quickly-toward-1-000-employees.html | archive-date=29 October 2020 | url-status=live}}

=2020–present=

In January 2020, Catalent purchased a manufacturing facility located in Anagni, Italy, from Bristol-Myers Squibb, to manufacture and package biologic and oral solid dose products for multiple companies.{{Cite press release | url=https://news.bms.com/news/details/2020/Bristol-Myers-Squibb-Completes-Divestment-of-Manufacturing-Facility-in-Anagni-Italy/default.aspx | title=Bristol-Myers Squibb Completes Divestment of Manufacturing Facility in Anagni, Italy | publisher=Business Wire | location=New York City | date=January 7, 2020}}

In February 2020, Catalent agreed to acquire MaSTherCell, a Belgian gene and cell therapy manufacturer, for $315 million, to expand into cell therapy development.{{Cite news | url=https://www.fiercepharma.com/manufacturing/catalent-laying-out-315m-to-snatch-another-gene-therapy-cdmo | title=Catalent laying out $315M to snatch another gene therapy CDMO | first=Eric | last=Palmer | work=Fierce Pharma | date=February 3, 2020}}{{Cite news | url=https://www.manufacturingchemist.com/news/article_page/Catalent_adds_to_regenerative_therapy_portfolio_with_315m_acquisition/162009 | title=Catalent adds to regenerative therapy portfolio with $315m acquisition | work=Manufacturing Chemist | date=February 3, 2020}}

In 2020, Catalent partnered with multiple drugmakers, including Pfizer, Johnson & Johnson,{{Cite news | url=https://www.cnbc.com/2020/05/08/pfizer-to-outsource-some-drug-production-focus-on-coronavirus-vaccine.html | title=Pfizer to outsource some drug production, focus on coronavirus vaccine | agency=Reuters | work=CNBC | date=May 9, 2020}} AstraZeneca,{{Cite news | url=https://www.reuters.com/article/business/astrazeneca-picks-catalent-for-packaging-potential-covid-19-vaccine-idUSL4N2DS2XI/ | title=AstraZeneca Picks Catalent for Packaging, Supplying Potential COVID-19 Vaccine | first=Saumya Sibi | last=Joseph | editor-first=Saumyadeb | editor-last=Chakrabarty | work=Reuters | date=June 15, 2020}} and Moderna{{Cite news | url=https://www.barrons.com/articles/moderna-coronavirus-vaccine-partner-catalent-production-51593099741 |title=Moderna Is the Latest Coronavirus Vaccine Partner for Catalent | work=Barron's | archive-url=https://web.archive.org/web/20200625155958/https://www.barrons.com/articles/moderna-coronavirus-vaccine-partner-catalent-production-51593099741 |archive-date=25 June 2020 | url-status=live}} to provide manufacturing, vial filling and packaging capabilities for COVID-19 vaccines.{{Cite news | url=https://www.wsj.com/articles/geopolitical-power-play-over-coronavirus-vaccine-leaves-drugmakers-in-the-middle-11590577849 | title='Vaccine Nationalism': A New Dynamic in the Race to Quash Coronavirus | first1=Peter | last1=Loftus | first2=Drew | last2=Hinshaw | work=The Wall Street Journal |date=May 27, 2020 | url-access=subscription}}{{Cite news | url=https://www.reuters.com/article/us-health-coronavirus-vaccines-manufactu-idUSKBN23W1ND |title=Vaccine makers face biggest medical manufacturing challenge in history | first1=Julie | last1=Steenhuysen | first2=Kate | last2=Kelland | work=Reuters |date=June 25, 2020}} In the partnership with AstraZeneca, Catalent provided manufacturing from its Maryland facility and vial filling and packaging from its Italian facility.{{Cite news |url=https://www.bizjournals.com/baltimore/news/2020/08/26/catalent-to-manufacture-covid-19-vaccine-in-md.html | title=AstraZeneca taps Catalent Inc. to manufacture Covid-19 vaccine candidate in Maryland | first=Morgan | last=Eichensehr | work=American City Business Journals | date=August 26, 2020 | url-access=subscription}} Catalent also partnered with ViralClear to manufacture a COVID-19 treatment candidate at Catalent's facility in St. Petersburg, Florida.{{Cite news |url=https://www.bizjournals.com/tampabay/news/2020/06/23/why-this-medical-company-partnered-with-a-st-pete.html | title=Manufacturer to help develop potential Covid treatment at St. Pete facility | first=Veronica | last=Brezina-Smith | work=American City Business Journals | date=June 23, 2020 | url-access=subscription}}

In August 2021, Catalent acquired German gene therapy development firm Rheincell Therapeutics.{{Cite news | title=Catalent Finalizes RheinCell Therapeutics Acquisition | url=https://www.biopharminternational.com/view/catalent-finalizes-rheincell-therapeutics-acquisition | work=BioPharm International | date=August 6, 2021 | archive-url=https://web.archive.org/web/20210809213536/https://www.biopharminternational.com/view/catalent-finalizes-rheincell-therapeutics-acquisition | archive-date=9 August 2021 | url-status=live}} That month, Catalent also acquired Bettera Holdings, a nutritional supplement company, for $1 billion to provide capability to manufacture vitamins, minerals and supplements in gummy form.{{Cite news | url=https://www.wsj.com/articles/catalent-to-buy-supplement-maker-bettera-holdings-for-1-billion-11630274401 | title=Catalent to Buy Supplement Maker Bettera Holdings for $1 Billion | last=Hopkins | first=Jared S. |work=The Wall Street Journal |date=August 30, 2021 | url-access=subscription |issn=0099-9660}}

In October 2021, Catalent opened a 6,000 square-meter clinical supply facility in Shiga, Japan.{{Cite news | url=https://www.biospace.com/article/crmo-catalent-on-a-roll-expects-to-add-500-to-600-jobs-in-indiana/ | title=Catalent's Momentum Continues with Up to 600 New Jobs Being Added | first=Mark | last=Terry | work=BioSpace | date=October 22, 2021}}

In August 2022, the company acquired Metrics Contract Services, a contract manufacturing organization, for $475 million.{{Cite news | url=https://www.fiercepharma.com/manufacturing/new-ceo-maselli-continues-catalents-expansion-blitz-475m-buyout-cdmo-metrics | title=New CEO Maselli extends Catalent's expansion blitz with $475M buyout of CDMO Metrics | first=Kevin | last=Dunleavy | work=Fierce Pharma | date=August 10, 2022}}

In October 2022, Catalent announced a $12M expansion at a Kansas City, Missouri facility.{{Cite news | url=https://www.contractpharma.com/contents/view_breaking-news/2022-10-20/catalent-announces-12-million-expansion-program-at-kansas-city-facility/ | title=Catalent Announces $12 Million Expansion Program at Kansas City Facility | work=Contract Pharma | date=October 20, 2022}}

In January 2023, Catalent partnered with Sarepta Therapeutics to manufacture delandistrogene moxeparvovec (SRP-9001). Sarepta's most advanced gene therapy candidate for the treatment of Duchenne muscular dystrophy (DMD).{{Cite news |url=https://www.fiercepharma.com/manufacturing/catalent-inks-deal-manufacture-sareptas-dmd-gene-therapy | title=Catalent inks deal to manufacture Sarepta's DMD gene therapy | last=Keenan | first=Joseph | work=Fierce Pharma | date=January 5, 2023}}{{Cite press release | title=Sarepta and Catalent Expand Strategic Manufacturing Partnership With Commercial Supply Agreement for Duchenne Muscular Dystrophy Gene Therapy Candidate | url=https://www.businesswire.com/news/home/20230105005445/en/Sarepta-and-Catalent-Expand-Strategic-Manufacturing-Partnership-With-Commercial-Supply-Agreement-for-Duchenne-Muscular-Dystrophy-Gene-Therapy-Candidate | publisher=Business Wire | date=January 5, 2023}}

In December 2024, Novo Holdings A/S acquired Catalent for $16.5{{nbsp}}billion. As part of the transaction, Novo Nordisk acquired three manufacturing facilities from parent Novo Holdings for $11{{nbsp}}billion to scale up production to meet the demand of Wegovy and Ozempic.{{Cite news | last=Gilbert | first=Daniel | title=Novo Nordisk buys manufacturing power as it seeks to ramp up Wegovy | url=https://www.washingtonpost.com/business/2024/02/05/novo-nordisk-catalent-wegovy-ozempic/ | newspaper=The Washington Post | date=February 5, 2024}}{{Cite news | last=Constantino |first=Annika Kim |title=Novo Nordisk parent to buy Catalent for $16.5 billion to expand Wegovy supply | url=https://www.cnbc.com/2024/02/05/novo-nordisk-parent-to-buy-catalent-to-expand-wegovy-supply.html | work=CNBC | date=February 5, 2024}}